These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 20683883

  • 1. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P.
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [Abstract] [Full Text] [Related]

  • 2. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
    [Abstract] [Full Text] [Related]

  • 3. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [Abstract] [Full Text] [Related]

  • 4. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P.
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [Abstract] [Full Text] [Related]

  • 5. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K.
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [Abstract] [Full Text] [Related]

  • 6. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT.
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF.
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [Abstract] [Full Text] [Related]

  • 8. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 9. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT.
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [Abstract] [Full Text] [Related]

  • 10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 11. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
    Roschger P, Manjubala I, Zoeger N, Meirer F, Simon R, Li C, Fratzl-Zelman N, Misof BM, Paschalis EP, Streli C, Fratzl P, Klaushofer K.
    J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
    [Abstract] [Full Text] [Related]

  • 12. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 14. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
    Misof BM, Roschger P, Gabriel D, Paschalis EP, Eriksen EF, Recker RR, Gasser JA, Klaushofer K.
    J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
    [Abstract] [Full Text] [Related]

  • 15. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
    Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K.
    Spine (Phila Pa 1976); 2013 Apr 15; 38(8):E487-92. PubMed ID: 23354115
    [Abstract] [Full Text] [Related]

  • 16. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.
    Bone; 2012 Jan 15; 50(1):165-70. PubMed ID: 22015818
    [Abstract] [Full Text] [Related]

  • 17. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B, Gamsjaeger S, Varga F, Dobnig H, Stepan JJ, Petto H, Pavo I, Klaushofer K, Paschalis EP.
    Osteoporos Int; 2014 Dec 15; 25(12):2709-19. PubMed ID: 25037600
    [Abstract] [Full Text] [Related]

  • 18. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S.
    Calcif Tissue Int; 2011 Aug 15; 89(2):130-9. PubMed ID: 21626160
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
    Ma YL, Marin F, Stepan J, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Martínez G, Malouf J, Zeng QQ, Wan X, Recker RR.
    Bone; 2011 May 01; 48(5):972-8. PubMed ID: 21262402
    [Abstract] [Full Text] [Related]

  • 20. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr 01; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.